Hikma Pharmaceuticals (STU:H5P) Margin of Safety % (DCF FCF Based): -237.90% (As of Jun. 27, 2026)


STU:H5P Hikma Pharmaceuticals PLC STU:H5P
80 GF Score
Price €17.74
GF Value €24.40
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Hikma Pharmaceuticals STU:H5P 80 Margin of Safety % (DCF FCF Based) is -237.90% as of Jun. 27, 2026. GuruFocus rates STU:H5P with a GF Score™ of 80/100 and a GF Value™ of €24.40 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-27), Hikma Pharmaceuticals's Predictability Rank is 3.5-Stars. Hikma Pharmaceuticals's intrinsic value calculated from the Discounted FCF model is €25.92 and current share price is €17.74. Consequently,

Hikma Pharmaceuticals's Margin of Safety % (DCF FCF Based) using Discounted FCF model is -237.90%.

STU:H5P vs ZTS, UTHR, VTRS: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


STU:H5P
80GF Score
Hikma Pharmaceuticals PLC STU:H5P
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Margin of Safety % (DCF FCF Based) Calculation

Hikma Pharmaceuticals's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(5.25-17.74)/5.25
=-237.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

What does a Margin of Safety % (DCF FCF Based) of -237.90% mean?
Hikma Pharmaceuticals (STU:H5P) has a Margin of Safety % (DCF FCF Based) of -237.90% as of Jun. 27, 2026. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Hikma Pharmaceuticals.
Is Hikma Pharmaceuticals' Margin of Safety % (DCF FCF Based) too high?
Hikma Pharmaceuticals' current Margin of Safety % (DCF FCF Based) is -237.90%. Overall, Hikma Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Margin of Safety % (DCF FCF Based) compare to ZTS and UTHR?
Hikma Pharmaceuticals' Margin of Safety % (DCF FCF Based) of -237.90% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF FCF Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF FCF Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF FCF Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF FCF Based) mean?
A high Margin of Safety % (DCF FCF Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Hikma Pharmaceuticals. Hikma Pharmaceuticals's current Margin of Safety % (DCF FCF Based) is -237.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (STU:H5P) is currently considered Modestly Undervalued. The stock's GF Value™ is €24.40, compared to a current price of €17.74 — trading 27.3% below its estimated fair value. The current Margin of Safety % (DCF FCF Based) is -237.90%. Hikma Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF FCF Based) calculated?
Margin of Safety % (DCF FCF Based) is calculated from a company's financial statements. For Hikma Pharmaceuticals (STU:H5P), the current Margin of Safety % (DCF FCF Based) is -237.90% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (STU:H5P) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of €17.74 is trading 27.3% below its estimated GF Value™ of €24.40. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:H5P:

  • Margin of Safety % (DCF FCF Based): -237.90%
  • GF Value™: €24.40 vs. price of €17.74 (27.3% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the STU:H5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
80GF Score

Get the complete analysis for STU:H5P

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.74
Price
€24.40
GF Value